SCIENTIFIC PROGRAMME
SESSION I
THE GENOMIC AND
EPIGENOMIC LANDSCAPE
OF CLL AND CLINICAL
CONSEQUENCES
SESSION II
THE ROLE OF BCR
ACTIVATION AND
SIGNALLING FOR CLL
SESSION III
THERAPEUTIC OPTIONS
FOR CLL
SESSION IV
LONG TERM FOLLOW
UP OF CLINICAL TRIALS
VERSUS REAL WORLD
DATA (OUTSIDE CLINICAL
TRIALS DATA-OCT)
SESSION V
THE INCREASING ROLE
OF THE LEUKAEMIC
MICROENVIRONMENT
SESSION VI
THERAPEUTIC OPTIONS 2 :
THE USE OF CELLULAR
AND NON-CELLULAR
IMMUNOTHERAPIES IN
CLL
SESSION VII
EFFICACY THROUGH
SAFETY
SESSION VIII
CLONAL HETEROGENEITY,
CLONAL EVOLUTION AND
MECHANISMS OF DRUG
RESISTANCE
SESSION IX
CONTRASTING
THERAPEUTIC CONCEPTS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES
SELECTED ABSTRACTS FOR POSTER PRESENTATIONS
IN ALPHABETIC ORDER ACCORDING TO THE NAME OF THE FIRST AUTHOR
CLINICAL POSTERS
Poster 28: BLOOD CELLULAR HAEMATOLOGICAL CHANGES IN PATIENTS WITH VISCERAL
LEISHMANIASIS ATTENDING KIMALEL SUB-COUNTY HOSPITAL, BARINGO
COUNTY
Lukas Agura, Kahato M, Kibet S
Poster 29: ANTI-LEUKEMIC EFFECTS OF SYK INHIBITION IN PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL) TREATED ON THE PHASE I/II STUDY OF
ENTOSPLETINIB (ENTO) IN COMBINATION WITH OBINUTUZUMAB
Scott Best, Vi Lam, Adam Kittai and Alexey Danilov
Poster 30: CHRONIC NEUTROPHILIC LEUKEMIA AFTER CHRONIC LYMPHOCYTIC
LEUKEMIA
Maria Eduarda Couto, Susana Bizarro, Domingos Sousa, Nelson Domingues,
Isabel Oliveira, Manuel Teixeira and José Mariz
Poster 31: LONG-TERM EFFICACY AND SAFETY OF MAINTENANCE WITH LENALIDOMIDE
IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA AND A HIGH RISK
OF PROGRESSION AFTER FIRST-LINE IMMUNOCHEMOTHERAPY
Anna Fink, Sandra Robrecht, Can Zhang, Moritz Fürstenau, Ali Aldaoud, Holger
Hebart, Kathleen Jentsch-Ullrich, Steffen Doerfel, Kirsten Fischer, Clemens
Wendtner, Thomas Noesslinger, Paolo Ghia, Francesc Bosch, Arnon Kater,
Hartmut Döhner, Michael Kneba, Karl-Anton Kreuzer, Eugen Tausch, Stephan
Stilgenbauer, Matthias Ritgen, Sebastian Böttcher, Barbara Eichhorst and
Michael Hallek
Poster 32: CLASSICAL PARAMETERS STILL PREDICT TREATMENT-FREE SURVIVAL IN THE
ERA OF NOVEL THERAPIES : ANALYSIS OF A CLL NATURAL HISTORY COHORT
Paul J. Hengeveld, Arnon P. Kater, Julie M. N. Dubois, Anton W. Langerak, Peter
E. Westerweel and Mark-David Levin
Poster 33: CLINICAL PRACTICE EXPERIENCE OF IBRUTINIB THERAPY
IN CHRONIC LYMPHOCYTIC LEUKEMIA
Francisca Miranda, Ana Jorge, Celina Afonso
Poster 34: GOOD RESPONSE TO FC-R IN PATIENT WITH LOW LEVEL DEL(17)P CLL CLONE
Cláudia Pedrosa, Rita Coutinho and Jorge Coutinho
Poster 35: OVEREXPRESSION OF AID AND LPL RELATED TO CLL-IPI PROGNOSTIC INDEX
AND ITS IMPACT ON TIME TO FIRST TREATMENT
Victoria Remedi, Ana Ines Landoni, Victoria Irigoin, Carolina Oliver, Cecilia
Guillermo, Lilian Diaz, Daniel Prieto, Angimar Uriepero, Pablo Oppezzo and Raúl
Gabús